Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789125 | 0.99 | ABCG2 (0.65) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8790688 | 0.94 | ABCG2 (0.70) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8789181 | 0.94 | ABCG2 (0.69) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8790131 | 0.94 | ABCG2 (0.72) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8788917 | 0.94 | ABCG2 (0.72) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8790230 | 0.91 | ABCG2 (0.66) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8789900 | 0.88 | ABCG2 (0.68) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8836061 | 0.88 | ABCG2 (0.63) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8790888 | 0.87 | ABCG2 (0.60) | ABCG2MAPTTP53MEN1KMT2A | |
| SCHEMBL8789743 | 0.87 | ABCG2 (0.58) | ABCG2MAPTTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |